Clinical trials: Allergic Bronchopulmonary Aspergillosis (ABPA)
Severe Asthma, Allergic Bronchopulmonary Aspergillosis (ABPA)
Modeling Bronchial Epithelium in Severe Asthma With Human Induced Pluripotent Stem Cells (iPSC)
Asthma is severe when it cannot be controlled with maximum-dose inhaled therapies while management of comorbidities and other precipitating or aggravating factors has been optimized.
- Trial name
- MOSAIC (NCT05616338)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 4 people
- Sponsor
- University Hospital, Montpellier
Allergic Bronchopulmonary Aspergillosis, ABPA
Real-World Effectiveness of Depemokimab in Allergic Bronchopulmonary Aspergillosis With Severe Eosinophilic Asthma
An open-label study will evaluate effects of Depemokimab in the treatment of severe eosinophilic asthma in patients with allergic bronchopulmonary aspergillosis
- Conditions
- Allergic Bronchopulmonary Aspergillosis, ABPA, Severe Eosinophilic Asthma
- Trial name
- NCT07828327
- Testing
- Depemokimab
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Qianfoshan Hospital
Allergic Bronchopulmonary Aspergillosis, Severe Asthma
Real-World Effectiveness of Tezepelumab in Allergic Bronchopulmonary Aspergillosis
An open-label study will evaluate effects of Tezepelumab in the treatment of severe asthma in patients with allergic bronchopulmonary aspergillosis
- Conditions
- Allergic Bronchopulmonary Aspergillosis, Severe Asthma, ABPA
- Trial name
- NCT07757841
- Testing
- Tezepelumab
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Qianfoshan Hospital
ABPA, Allergic Bronchopulmonary Aspergillosis
ML-Based ABPA Recurrence Prediction and Clinical Utility
This multicenter bidirectional cohort study aims to develop and externally validate a machine learning model for predicting the risk of acute exacerbation within 1 year in patients with allergic bronchopulmonary aspergillosis…
- Conditions
- ABPA, Allergic Bronchopulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis (ABPA), Acute Exacerbation
- Trial name
- ABPA-ML (NCT07714863)
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Qianfoshan Hospital
ABPA, Allergic Bronchopulmonary Aspergillosis
Fungal Status and Prognosis in ABPA
This multicenter bidirectional cohort study aims to investigate the clinical characteristics and prognostic outcomes of patients with allergic bronchopulmonary aspergillosis (ABPA) stratified by fungal microbiological status in…
- Conditions
- ABPA, Allergic Bronchopulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis (ABPA), Colonization
- Trial name
- ABPAFUNGAL (NCT07690345)
- Where
- China
- Volunteers
- 114 people
- Sponsor
- Qianfoshan Hospital
Allergic Bronchopulmonary Aspergillosis (ABPA), Machine Learning
Multi-Omics Inflammatory Phenotype for ABPA Recurrence Risk Prediction
To develop and externally validate a machine learning model for predicting the 1-year risk of relapse in patients with stable ABPA, and to further evaluate its value in risk stratification and clinical decision-making.
- Conditions
- Allergic Bronchopulmonary Aspergillosis (ABPA), Machine Learning, Multi-omics, Multicenter Study
- Trial name
- NCT07611838
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Qianfoshan Hospital
Allergic Bronchopulmonary Aspergillosis, Severe Asthma
Real-World Effectiveness of Benralizumab in Allergic Bronchopulmonary Aspergillosis
An open-label study will evaluate effects of Benralizumab in the treatment of severe asthma in patients with allergic bronchopulmonary aspergillosis
- Conditions
- Allergic Bronchopulmonary Aspergillosis, Severe Asthma, ABPA
- Trial name
- NCT07530770
- Testing
- Fasenra
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Qianfoshan Hospital
ABPA, Biologics
A Cohort Study of the Efficacy and Safety of Biologics in Patients With ABPA
To evaluate the efficacy and safety of biological agents in patients with allergic bronchopulmonary aspergillosis.
- Conditions
- ABPA, Biologics, Allergic Bronchopulmonary Aspergillosis (ABPA), Cohort Study
- Trial name
- NCT07362693
- Testing
- Biologic Agent
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Qianfoshan Hospital
Airway Inflammation, Chronic Obstructive Pulmonary Disease (COPD)
Immune Status and Disease Control of Inflammatory Airway Diseases
The goal of this study is to learn how the body's immune system affects disease control in people with different airway inflammatory diseases.We want to understand: 1.Whether specific immune cell patterns in the blood are linked…
- Conditions
- Airway Inflammation, Chronic Obstructive Pulmonary Disease (COPD), Asthma (Diagnosis), Bronchiectasis
- Trial name
- ISDC-IAD (NCT07493629)
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Ningbo University
ABPA, Allergic Bronchopulmonary Aspergillosis
A Study of the Efficacy and Safety of Bronchoscopic Airway Clearance and Amphotericin B Spraying in Patients With ABPA
To evaluate the efficacy and safety of bronchoscopic airway clearance and amphotericin B spraying in the treatment of allergic bronchopulmonary aspergillosis
- Conditions
- ABPA, Allergic Bronchopulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis (ABPA), Airway Clearance
- Trial name
- NCT07362667
- Testing
- The patients were treated with bronchoscopic airway clearance and amphotericin B spraying
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Qianfoshan Hospital
Allergic Bronchopulmonary Aspergillosis (ABPA)
Interest of IgE Directed Against Recombinant Antigens of Aspergillus Fumigatus in the Diagnosis of Allergic Bronchopulmonary Aspergillosis (ABPA)
Allergic Bronchopulmonary Aspergillosis is a rare pulmonary disease involving allergic mechanisms, which historically affects patients with asthma or cystic fibrosis only. It is a source of respiratory decompensation.
- Trial name
- BPCO (NCT07055230)
- Where
- France
- Volunteers
- 67 people
- Sponsor
- University Hospital, Rouen
Allergic Bronchopulmonary Aspergillosis (ABPA)
Pathogenesis and Inflammatory Phenotype of Allergic Bronchopulmonary Aspergillosis
This study aims to reveal the immune and inflammatory regulatory molecular mechanisms related to the progression of allergic bronchopulmonary aspergillosis (ABPA), and to build a precision typing based on inflammation and…
- Trial name
- NCT07040332
- Where
- China
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Qianfoshan Hospital
ABPA
Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPA
The goal of this clinical trial is to learn about PUR1900 as an inhaled, antifungal therapeutic for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma.
- Trial name
- NCT05667662
- Testing
- Itraconazole Powder
- Where
- 18 sites in United States, Australia and 2 more
- Volunteers
- 8 people
- Sponsor
- Pulmatrix Inc.
Allergic Bronchopulmonary Aspergillosis, Asthma
Allergic Bronchopulmonary Aspergillosis Prescreening Study
This prescreening study is being conducted to diagnose ABPA in selected patients with asthma and to increase the potential number of eligible participants for the ongoing Study 601-0018 of PUR1900 in subjects with ABPA.
- Conditions
- Allergic Bronchopulmonary Aspergillosis, Asthma, ABPA
- Trial name
- NCT05903612
- Where
- United Kingdom
- Sponsor
- Community Pharmacology Services Ltd
ABPA, Severe Asthma
Benralizumab in the Treatment of Patients With Severe Asthma With ABPA
Phase IV, open-label study will evaluate effects of Benralizumab in the treatment of severe asthma in patients with allergic bronchopulmonary aspergillosis
- Conditions
- ABPA, Severe Asthma, Allergic Bronchopulmonary Aspergillosis
- Trial name
- NCT04108962
- Testing
- Fasenra, 30 Mg/mL Subcutaneous Solution
- Where
- United States
- Sponsor
- Baylor Research Institute